Combination Therapy for Cancer – Oral Fenretinide and Microtubule inhibitors
- 详细技术说明
- TechSummary: This inventioncombines fenretinide with microtubule inhibitors to increase thetherapeutic effect of fenretinide as an anti-cancer drug.
- *Abstract
-
Technology Summary: Combines fenretinide with microtubule inhibitors to increase its therapeutic effect as an anti-cancer drug.
Background: This invention is related to Fenretinide (4-hydroxy(phenyl) retinamide), a synthetic retinoid derivative that has been investigated for potential use in the treatment of cancer and some other diseases, such as macular degeneration. Specific types of cancer investigated include bladder, breast, Non-Hodgkin's lymphoma, neuroblastoma, and Ewing's sarcomaBioavailability of the long-established fenretinide formulation has been a limiting factor in achieving optimal therapeutic benefit.
Technology Description: This invention proposes the use of fenretinide, a well known anticancer agent, in combination with microtubule inhibitors. These inhibitors are another important class of anti-cancer agents.Pre-clinical data from multiple tumor xenograft models show that fenretinide is more effective when used with microtubule inhibitors instead of as a single agent.
The combination of fenretinide and microtubule inhibitors is well-tolerated in mice. Its synergistic effect presents a novel treatment approach in oncology.
Applications:- Cancer treatment
- Macular degeneration
Advantages:- Orally administered
- Improved bioavailability
- Improved anti-tumor activity of fenretinide
Development Stage: Pre-clinical proof of principle data.
IP Protection: PCT application filed PCT/US2007/011686
- *IP Issue Date
- May 16, 2007
- *IP Type
- Other Patent
- 国家
- United States
- 申请号码
- PCT/US2007/011686
- 国家/地区
- 美国
